The Canadian Press - ONLINE EDITION

Serious ethical questions arise over experimental Ebola drug after only 3 Westerners get it

  • Print
In this photo taken Saturday, Aug. 9, 2014, volunteers prepare basic supplies donated to the Ebola treatment center by American donors, as they fight the deadly Ebola virus at the Kenema Government Hospital in Kenema, 300 kilometers, (186 miles) from the capital city of Freetown, Sierra Leone. Over the decades, Ebola cases have been confirmed in 10 African countries, including Congo where the disease was first reported in 1976. But until this year, Ebola had never come to West Africa. (AP Photo/ Michael Duff)

Enlarge Image

In this photo taken Saturday, Aug. 9, 2014, volunteers prepare basic supplies donated to the Ebola treatment center by American donors, as they fight the deadly Ebola virus at the Kenema Government Hospital in Kenema, 300 kilometers, (186 miles) from the capital city of Freetown, Sierra Leone. Over the decades, Ebola cases have been confirmed in 10 African countries, including Congo where the disease was first reported in 1976. But until this year, Ebola had never come to West Africa. (AP Photo/ Michael Duff)

MADRID - In a development that raises a host of ethical issues, Spain announced it had obtained a scarce U.S.-made experimental Ebola drug to treat a Spanish missionary priest infected with the killer virus.

So far the experimental drug ZMapp has been used to treat two infected Americans and a Spaniard but no Africans for a hemorrhagic disease that has been ravaging West Africa for months and has killed about 50 per cent of those it infects. That news came as medical experts debated the ethical questions surrounding experimental Ebola drugs and vaccines during a teleconference Monday organized by the U.N. health agency.

There is no known cure or licensed treatment for Ebola, which has killed over 960 people in the current outbreak in West Africa. The World Health Organization has called the Ebola outbreak — which emerged in Guinea in March and has since spread to Liberia, Sierra Leone and possibly Nigeria — an international health emergency and urged nations worldwide to battle the disease.

The drug's maker, Mapp Pharmaceutical Inc. of San Diego, says on its website that "very little of the drug is currently available" and that it is co-operating with government agencies to increase production as quickly as possible.

Nigerian officials say they had asked U.S. health authorities about getting the Ebola drug last week.

"It certainly looks bad that only three Westerners have gotten the drug while most of the people with Ebola are African," said Art Caplan, director of bioethics at NYU Langone Medical Center. He said the drugmaker must make its policy for distributing its treatment clear. "I don't think this scarce resource should just be given to whoever is best connected."

Still, Caplan said there might be a reasonable explanation for why only Westerners were given the drug, including the need for a sophisticated medical centre to administer it and monitor the patient carefully since the drug hasn't been tested in humans.

But some Africans said giving the experimental drug only to Westerners was patently unfair.

"There's no reason to try this medicine on sick white people and to ignore blacks," said Marcel Guilavogui, a pharmacist in Conakry, Guinea. "We understand that it's a drug that's being tested for the first time and that could have negative side effects. But we have to try it in blacks too."

In Nigeria, which says it has 10 confirmed cases of Ebola, some people began demanding the serum on Twitter. The World Health Organization has not yet confirmed the Nigerian cases.

In a statement, the Spanish Health Ministry said the ZMapp drug was obtained in Geneva this weekend with permission from the company and brought to Madrid to treat Miguel Pajares. The 75-year-old priest was evacuated from Liberia and placed in isolation Thursday at Madrid's Carlos III Hospital.

Two Americans diagnosed with Ebola in Liberia and evacuated back to the United States have been treated with the drug. One of them, Dr. Kent Brantly, said last week that his condition was improving and the husband of the aid worker being treated with Brantly said the same thing.

The drug is made at Kentucky BioProcessing for Mapp Biopharmaceutical. A spokesman for Kentucky BioProcessing said last week that it complied with a request from the international relief group Samaritan's Purse and Emory University Hospital in Atlanta and provided a limited amount of the drug. Brantly works for Samaritan's Purse and both Americans are being cared for now at Emory.

It was not exactly clear how Spain got the drug and authorities refused to comment about any possible costs involved. Geneva University Hospital told The Associated Press it was involved in getting the drug to Spain but would not elaborate.

In its statement, Spain's Health Ministry said "the medicine was imported from Geneva where there was one dose available in the context of an accord between the laboratory that developed the medicine, WHO and (Doctors Without Borders)."

It said Spain sought the drug under a Spanish law that permits the use of unauthorized medication for patients with a life-threatening illness who cannot be treated satisfactorily by authorized drugs.

At least two countries in West Africa have expressed interest in the drug. Nigeria's health minister, Onyenbuchi Chukwu, said last week he had asked U.S. health officials about access to it but was told the manufacturer would have to agree. Guinea also said Monday it would like to have some of the drug.

"Guinean authorities would naturally be interested in having this medicine," said Alhoussein Makanera Kake, spokesman for the government committee fighting Ebola.

Because the ZMapp drug has never been tested in humans, scientists say there's no way to tell if it has made any difference to the two American aid workers who have received it.

The drug is a mixture of three antibodies engineered to recognize Ebola and bind to infected cells so the immune system can kill them. Scientists culled antibodies from laboratory mice and ZMapp's maker now grows the antibodies in tobacco plants and then purifies them. It takes several months to even produce a modest amount of the drug.

The U.N. health agency planned to hold a news conference Tuesday to discuss the ethics meeting.

In other Ebola developments Monday:

— A Catholic humanitarian group based in Spain said that another religious worker and colleague of the infected Spanish priest had died in from Ebola in Liberia.

— Nigerian health authorities confirmed another Ebola case Monday, a nurse who had treated Patrick Sawyer, the Liberian-American who flew into Nigeria and died last month. That brings the locally confirmed Ebola cases in Nigeria to 10, including the two who have died, Sawyer and another nurse. Nigerian authorities now have 177 contacts of Sawyer under surveillance.

— Liberia announced that a donation of protective gear from China was arriving Monday. A shortage of full-body suits and even clean surgical gloves has left health workers exposed to the virus and prompted some to refuse to treat Ebola patients.

— George Weah, a former FIFA world player of the year from Liberia, has joined the efforts to spread awareness about the disease and how to prevent it. He recorded a song titled "Ebola is real," and proceeds are going to the Liberian Health Ministry.

___

Medical writer Cheng reported from London. AP writers Jonathan Paye-Layleh from Monrovia, Liberia, Boubacar Diallo in Gonakry, Guinea and Bashir Adigun from Abuja, Nigeria, also contributed to this report.

Fact Check

Fact Check

Have you found an error, or know of something we’ve missed in one of our stories?
Please use the form below and let us know.

* Required
  • Please post the headline of the story or the title of the video with the error.

  • Please post exactly what was wrong with the story.

  • Please indicate your source for the correct information.

  • Yes

    No

  • This will only be used to contact you if we have a question about your submission, it will not be used to identify you or be published.

  • Cancel

Having problems with the form?

Contact Us Directly
  • Print

You can comment on most stories on winnipegfreepress.com. You can also agree or disagree with other comments. All you need to do is be a Winnipeg Free Press print or e-edition subscriber to join the conversation and give your feedback.

You can comment on most stories on winnipegfreepress.com. You can also agree or disagree with other comments. All you need to do is be a Winnipeg Free Press print or e-edition subscriber to join the conversation and give your feedback.

Have Your Say

New to commenting? Check out our Frequently Asked Questions.

Have Your Say

Comments are open to Winnipeg Free Press print or e-edition subscribers only. why?

Have Your Say

Comments are open to Winnipeg Free Press Subscribers only. why?

The Winnipeg Free Press does not necessarily endorse any of the views posted. By submitting your comment, you agree to our Terms and Conditions. These terms were revised effective April 16, 2010.

letters

Make text: Larger | Smaller

LATEST VIDEO

Police speak out on Red River search

View more like this

Photo Store Gallery

  • A mother goose has chosen a rather busy spot to nest her eggs- in the parking lot of St Vital Centre on a boulevard. Countless cars buzz by and people have begun to bring it food.-Goose Challenge Day 06 - May 08, 2012   (JOE BRYKSA / WINNIPEG FREE PRESS)
  • June 25, 2013 - 130625  -  A storm lit up Winnipeg Tuesday, June 25, 2013. John Woods / Winnipeg Free Press - lightning

View More Gallery Photos

Poll

Do you think volunteers dragging the Red River is a good idea?

View Results

Ads by Google